Manage settings
MENU
About this site
In het Nederlands
Home
Researchers
Projects
Organisations
Outputs & Impact
Infrastructure
Contact
Research Explorer
Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.
Project
Accellerating towards clinical validation of Galsome nanovaccines
Information
Project Team
Organisations
Outputs & Impact
Publications & research data ( 2 )
Preclinical toxicological assessment of an α-galactosylceramide-adjuvanted mRNA cancer vaccine in Wistar Han rats and domestic pigs
Sofie Meulewaeter
Margo De Velder
Diethard Reckelbus
Kevin Mwangi
Thomas Ehouarne
Ilke Aernout
Yanou Engelen
Fëllanza Halimi
Isis Van herteryck
Lobke De Bels
et al.
A1
Journal Article
in
MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT
2025
Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria
Sofie Meulewaeter
Ilke Aernout
Joke Deprez
Yanou Engelen
Margo De Velder
Lorenzo Franceschini
Karine Breckpot
Serge Van Calenbergh
Caroline Asselman
Katie Boucher
et al.
A1
Journal Article
in
JOURNAL OF CONTROLLED RELEASE
2024
Activities ( 0 )
Results
Impact narratives ( 0 )
Patents ( 1 )
THERAPEUTIC NANOPARTICLES AND METHODS OF USE THEREOF
Patent application(s)
WO2020058239
( 25 March 2020 )
Patent application(s)
WO2020058239
( 25 March 2020 )
EP3852727
( 27 July 2021 )
Applicant(s)
Ghent University
Ghent University inventors
Heleen Dewitte
Ine Lentacker
Rein Verbeke
Stefaan De Smedt
Show more...